Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 8/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.59 |
| ▸ | MEN1 | O00255 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.57 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5467189 | 0.88 | DDX3X (0.66) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL3983832 | 0.86 | HPGD (0.65) | LMNAKMT2AMEN1GAASMN1; SMN2 | |
| SCHEMBL10955873 | 0.85 | LMNA (0.55) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL15821426 | 0.85 | SLC25A1 (0.65) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL13011714 | 0.84 | KMT2A (0.74) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL1495939 | 0.83 | FFAR4 (0.80) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL26931604 | 0.83 | GUSB (0.63) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL13999327 | 0.82 | ELANE (0.63) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL13999329 | 0.82 | LMNA (0.63) | LMNAKMT2AMEN1GAAMAPK1 | |
| SCHEMBL3278881 | 0.82 | LMNA (0.63) | LMNAKMT2AMEN1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731625-A1 | NEW SYNTHESIS METHOD | The Heart Research Institute Ltd (AU) | 2026-04-29 | — | — | EP | disclosed |
| WO-2024259491-A1 | NEW SYNTHESIS METHOD | THE HEART RESEARCH INSTITUTE LTD (AU) | 2024-12-26 | — | — | WO | disclosed |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2021-03-02 | — | — | US | disclosed |
| US-20190274979-A2 | USE OF (BENZENESULFONAMIDO)BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20190274979-A2 | USE OF (BENZENESULFONAMIDO)BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| US-20180333376-A1 | USE OF (BENZENESULFONAMIDO) BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | Hebei Medfaith Pharmaceutical Technology Co., Ltd. (CN) | 2018-11-22 | — | — | US | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| EP-1664002-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026134-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | LMNA 4188/4885KMT2A 3326/4885MEN1 4132/4885 |
| US-20180333376-A1 | USE OF (BENZENESULFONAMIDO) BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | COL1A1, COL2A1, COL14A1 | LMNA 745/4885KMT2A 1295/4885MEN1 4667/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | LMNA 3575/4885KMT2A 1633/4885MEN1 3853/4885 |
| US-20190274979-A2 | USE OF (BENZENESULFONAMIDO)BENZAMIDE COMPOUNDS FOR INHIBITING LIVER FIBROSIS | COL1A1, COL2A1, COL14A1 | LMNA 745/4885KMT2A 1295/4885MEN1 4667/4885 |
| US-10933038-B2 | Use of (benzenesulfonamido) benzamide compounds for inhibiting liver fibrosis | COL1A1, COL2A1, COL14A1 | LMNA 745/4885KMT2A 1295/4885MEN1 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.